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Background: When treating mentally ill criminal offenders, improving medication adherence is essential to
achieving goals, such as long-term stabilization of symptoms and the prevention of recidivism. Most subjects who
are treated under the Medical Treatment and Supervision Act have schizophrenia, which is considered a particularly
difficult disorder for which to improve medication adherence. For such patients, we developed a Medication
Discontinuation Program (MDP) that aims to improve medication adherence by discontinuing antipsychotic drugs
and monitoring changes in psychiatric symptoms. We examined whether there was any utility for the MDP on a
trial basis as well as whether it would be worthwhile to introduce the MDP to psychiatric programs.
Methods: We conducted the MDP with an intervention group (n = 7) and compared Drug Attitude Inventory-30
(DAI-30) scores before and after implementation of the MDP. We also categorized 30 questions of the DAI-30 into
three subscales: “awareness of the need for medication”, “awareness of the effects of psychiatric drugs”, and
“impression of medication”, and examined factors affecting improvement in medication adherence.
Results: The total DAI-30 score significantly increased after completion of the MDP (P = 0.002). Significant elevations
after completion of the MDP were also observed in the scores for three subscales of the DAI-30.
Conclusions: Our study suggests that the MDP has a possibility of improving medication adherence, and this
program might have multidirectional and stimulatory effects on each factor related to the improvement of
medication adherence.
Keywords: Medical Treatment and Supervision Act, Adherence, Medication Discontinuation Program,
Schizophrenia, Drug Attitude Inventory-30Background
The preparation of special treatment systems and facil-
ities is important so that mentally ill people who have
committed crimes can be provided with appropriate
treatment and avoid recidivism. However, no such sys-
tem was in place in the late 19th century when scientific
medicine was introduced to Japan. More surprisingly, no
system was developed in Japan until the early 21st cen-
tury. Forensic support services in Japan lag far behind
those in European countries and the United States, and* Correspondence: murasugk@hosp.go.jp
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unless otherwise stated.recently, this need was recognized. As a result, the Act
on Medical Care and Treatment for Persons Who Have
Caused Serious Cases Under the Condition of Insanity
(hereafter, the Medical Treatment and Supervision Act
(MTSA)) was signed into law on 15 July, 2005, as the
first law pertaining to the treatment and social reintegra-
tion of offenders with mental illness in Japan. The pur-
pose of the MTSA is to promote the social rehabilitation
of people who have committed serious criminal offenses
due to mental disorders. To achieve this goal, subjects
are provided with appropriate medical care and continu-
ous supervision to improve their psychiatric symptoms
and prevent their recidivism. The framework of the
MTSA is shown in Figure 1, and details have been re-
ported previously [1].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Framework of the Medical Treatment and Supervision Act (MTSA).
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to achieve the goals of the MTSA by (1) building a treat-
ment alliance between a person who is subject to the
MTSA and a multidisciplinary team consisting of a
psychiatrist, psychologist, nurse, occupational therapist,Figure 2 Structure of treatment provided under the Medical Treatmeand psychiatric social worker; (2) helping the patient
recognize the presence of a mental disorder and take re-
sponsibility for crimes caused by the illness; and (3)
deepening insight and introspection into the disease
(Figure 2).nt and Supervision Act (MTSA).
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the MTSA published by the Japanese Ministry of Health,
Labour and Welfare offer an approximately 18-month
hospitalization, which is divided into three treatment
phases: acute, recovery, and rehabilitation. Each phase
has the following main achievement goals: improving
symptoms, enhancing motivation in treatment, and es-
tablishing trust relationships with the persons who com-
mitted crimes in the acute phase; acquiring insight into
diseases and the ability to control oneself and improving
medication adherence in the recovery phase; and recov-
ering the ability to live and preparing for reintegration in
the rehabilitation phase (Figure 3). The improvement in
medical adherence is an extremely important treatment
issue for achieving treatment goals and social reintegra-
tion. Some reports show that denial of medication is an
important predictor of violence derived from psychotic
symptoms [2,3]. Moreover, Swartz et al. reported that
drug abuse combined with poor adherence to medica-
tion among inpatients with severe mental illness may
indicate a higher risk for violent behavior in the commu-
nity after discharge [4].
Most people who are treated under the MTSA have
schizophrenia [5]. Full medication adherence is re-
ported to be rare in schizophrenia compared with that
in other diseases [6]. The following factors are consid-
ered to be associated with medication adherence: patient-Figure 3 Process of hospital treatment provided under the Medical Tre
Program (MDP) was conducted in the early stages of the recovery phase, in wrelated factors [7-9], such as levels of insight, psychotic
symptoms, cognitive impairment, education level, disease
duration, and adaptation to society; medication-related
factors [10-12], such as the presence or absence of side ef-
fects and dosing frequency; and environmental factors
[9,12-14], such as the patient-physician relationship, fam-
ily support, and financial status.
To improve medication adherence, we provide disease
education and prescribing information along with single
atypical antipsychotic therapy, and many patients have
achieved social reintegration after receiving interven-
tions to improve medication adherence. However, there
were some patients who continue to deny the presence
of their illness and reject treatment because of poor
insight and lack of understanding of the need to take
medication. As far as we know, no studies in Japan or
European countries and the United States, the latter two
of which have a longer history of offering specialized ser-
vices and facilities for mentally ill offenders, have re-
ported an effective method to improve medication
adherence for patients refusing to take medication.
Therefore, we conducted a Medication Discontinu-
ation Program (MDP), which was developed to increase
awareness of the effects of psychiatric drugs and im-
prove patients’ insights into their own disease and medi-
cation adherence. The MDP accomplishes this goal by
having patients discontinue their medication and thenatment and Supervision Act (MTSA). The Medication Discontinuation
hich medical conditions were stabilized.
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After seeing these changes, it is hoped that patients will
recognize the importance of adhering to their medica-
tion regimen in the future to maintain more appropriate
behavior. The program was performed between patients
and a multidisciplinary team who worked to discontinue
antipsychotic drugs using an individually structured ap-
proach and monitor changes in psychiatric symptoms.
To examine whether there was any utility for the MDP,
we conducted the MDP with seven patients with schizo-
phrenia (intervention group) and compared Drug Atti-
tude Inventory-30 (DAI-30) scores before and after
implementation of the program [15]. The DAI-30 com-
prehensively estimates subjective reactions and attitudes
to antipsychotic drugs in patients with schizophrenia.




The present study was conducted for inpatients in the
Department of Forensic Psychiatry at Komoro Kogen
Hospital from March 2009 to August 2013. Subjects
undergoing the MDP were selected by experienced psy-
chiatrists who based their assessments on the Diagnostic
and Statistical Manual of Mental Disorders - Fourth Edi-
tion (DSM-IV) [16]. Subject selection criteria were as
follows: among patients who were diagnosed as having
schizophrenia, those who did not show improvement in
medication adherence during standard treatment, in-
cluding single atypical antipsychotic therapy, psychoedu-
cation on disease, and neuroleptics, and who exhibited
strong denial of their disease and medication refusal. For
subjects to monitor themselves and verbally express
their own condition after discontinuation of medication,
this study also specified the following inclusion criteria:
subjects had to have scored more than 70 on the full-
scale Wechsler Adult Intelligence Scale - Third Edition
(WAIS-III) and more than 41 on the Global Assessment
of Functioning (GAF), which indicates that the patient
has a moderate level of communication skills and no
tendency to hide their condition. A total of eight cases
with schizophrenia who had committed crimes due to
persecutory delusions met the above criteria (Table 1).
The age, gender, and crime of each participant are not
shown to maintain anonymity of participants. Case 2
was excluded from the study because he did not reach
the acceptable level of medication readministration cri-
teria after discontinuation of antipsychotic drugs. The
criteria used in the MDP provide a standard description
at which the subject has to resume taking antipsychotic
drugs according to the deterioration of psychotic symp-
toms (Table 2). The remaining seven cases (the interven-
tion group) were included in this study.Changes in patients’ attitudes toward medication may
influence other medical treatment programs conducted
during MDP implementation, for example, a program
for achieving self-management of medication. In this
program, patients are encouraged by nurses to take a
medicine voluntarily (only hypnotics in the intervention
group), considering the necessity, action, and side effects
of the drugs. To verify this point, a total of 17 subjects
with schizophrenia whose basic attributes matched those
of the subjects in the intervention group were used as a
non-intervention group (Table 1). Experienced psychia-
trists diagnosed these subjects based on DSM-IV criteria.
In conducting the program, special attention was paid
to selecting the subjects because medication discon-
tinuation, which is generally not done under usual
treatment, was to be performed for subjects whose
symptoms were stabilized by the effects of antipsychotic
drugs, although the subjects strongly wished to discon-
tinue medication. From an ethical perspective, we
carefully examined not only the risks for prolonged
hospitalization and recidivism due to aggravation of the
disease but also those for poor therapeutic responsive-
ness resulting from changes in biological functions,
including atrophy of the brain. Subjects in the interven-
tion group hoped strongly to interrupt their medica-
tion, even after they were given information about the
disadvantages of medication interruption during the
disease education portion of the program. In addition,
they were considered to have a high risk of interrupting
medication after hospital discharge. We believe that im-
proving medication adherence is essential to preventing
recidivism, which is the purpose of the MTSA. We also
believe that preventing recidivism cannot be accom-
plished by methods other than the MDP. This program
was fully examined and approved by the ethics commit-
tee of the Department of Forensic Psychiatry with
external psychiatrists. During the program, medical
conditions of the subjects undergoing medication
discontinuation were regularly and carefully assessed
by the multidisciplinary team. These team members
underwent specialized training to estimate psychiatric
symptoms as appropriately as possible, and the propri-
ety of continuing the program was examined in confer-
ence with all medical personnel to minimize bias as
well as ensure that the program was executed safely. In
addition, the details and implementation status of the
program were described in the subjects’ treatment
status records, which were regularly submitted to the
court, to seek judicial comments. Subjects were in-
formed in writing of the process for conducting the
program and medication readministration. In addition,
subjects were informed that they could withdraw from
the MDP at any time. Written consent was obtained
from all subjects.




















Intervention group Case 1 20 9.66 Graduate school 95 Present Absent 42 OLZ 300
Case 2b 2 0.58 Graduate school 110 Absent Absent 51 QTP 1,060.6
Case 3 16 0.25 Graduate school 114 Absent Absent 55 OLZ 200
Case 4 0.42 0.42 Undergraduate school 73 Present Present 51 RIS 600
Case 5 5 9.58 High school 88 Present Present 45 OLZ 600
Case 6 6 0.67 High school 89 Present Present 56 OLZ 300
Case 7 4 0.25 Undergraduate school 106 Absent Absent 63 RIS 200
Case 8 1 0.25 High school 77 Absent Present 55 OLZ 700
Non-intervention group Case a 2 0.67 High school 87 Present Present 58 OLZ 400
Case b 0.5 5 Undergraduate school 104 Present Present 42 RIS 1,000
Case c 1.67 7.33 Undergraduate school 122 Present Present 60 RIS 400
Case d 0.33 25.5 Undergraduate school 108 Present Present 61 OLZ 200
Case e 19.33 1 Graduate school 85 Present Present 33 OLZ 1,200
Case f 0.08 24.75 Undergraduate school 93 Present Present 53 OLZ 1,000
Case g 5 36.58 Junior high school 71 Present Absent 35 OLZ 800
Case h 1.41 11.33 High school 90 Present Present 42 QTP 2,218.2
Case i 4.25 0.58 High school 101 Absent Present 55 OLZ 650
Case j 5 0.33 High school 70 Absent Present 45 ARP 150
Case k 0.33 1.91 Graduate school 98 Present Present 53 OLZ 600
Case l 0.16 11.75 Undergraduate school 100 Present Absent 63 QTP 757.6
Case m 0.04 1.25 High school 85 Present Present 68 OLZ 100
Case n 5 0.25 Undergraduate school 78 Absent Present 62 QTP 606.06
Case o 5 0.16 Undergraduate school 114 Present Absent 55 OLZ 600
Case p 4 4 Undergraduate school 100 Present Present 61 RIS 400
Case q 0.08 34.75 High school 72 Present Present 57 OLZ 800
aNumbered cases underwent the intervention; lettered cases did not.
bCase 2 was excluded from this study because he did not reach an acceptable level of the medication readministration criteria after discontinuation of antipsychotic drugs and a failure to restart them.
DUP duration of untreated psychosis, WAIS-III Wechsler Adult Intelligence Scale - Third Edition, GAF Global Assessment of Functioning, CP chlorpromazine, OLZ olanzapine, QTP quetiapine, RIS risperidone, ARP aripiprazole,













Table 2 Monitoring sheet of “warning signs” and medication readministration criteria
Level 0 (Use of medication) Level 1 (Slightly unfavorable) Level 2 (Danger! Need for medication readministration)
(1) Sleep duration 7–8 h (1) Sleep duration 2–3 h (1) Day-night reversal (No sleep)
(2) Auditory hallucinations are present,
but not bothersome.
(2) Imagined voice occupies the person’s
thoughts.
(2) The person suffers from auditory hallucinations involving
multiple persons conversing with each other, and speaks to
himself/herself.
(3) Visual hallucinations of ambiguous
images persist for 10–20 s, but are not
bothersome.
(3) The person sees human faces as visual
hallucinations.
(3) The person sees faces as hallucinations all the time,
which disturbs his/her everyday life.
(4) The person looks calm and smiles
during conversation.
(4) The person uses awkward facial
expressions and is unable to carry out
conversations.
(4) The person looks scared, and is unable to carry out any
meaningful conversation.
(5) The person eats most meals without
stopping.
(5) Mealtime is often interrupted by visual
hallucinations.
(5) The amount of food the person eats decreases due to
visual hallucinations.
(6) The person bathes and changes
clothes every day.
(6) The person bathes and changes clothes
only every 3 days due to reasons other than
cold weather.
(6) The person bathes and changes clothes once a week
due to reasons other than cold weather.
(7) The person sometimes becomes
frustrated.
(7) The person is frustrated all the time. (7) The person hits things, such as a bed, using an object.
(8) The person is not bothered by
noise.
(8) The person becomes sensitive to sound,
and this startles and wakes up the person
during sleep.
(8) The person always feels that he/she is under attack from
sounds in the environment.
(9) The person can lead a peaceful and
quiet life.
(9) The person feels restless and exhausted
due to auditory hallucinations.
(9) The person is always walking around inside or outside
his/her room.
(10) The person focuses on and
participates in the program.
(10) The person has difficulties focusing on
the program.
(10) The person drops out of the program.
(11) The person usually has a relaxing
time in his/her room.
(11) The person is unable to stay in his/her
room.
(11) The person is unable to sit still.
Medication readministration criteria More than four choices One or more choices
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MDP implementation guidance
MDP implementation period The MDP was conducted
in the early stages of the recovery phase, in which med-
ical conditions were stabilized by antipsychotic drug
therapy, and basic disease education and psychoeduca-
tion on antipsychotic drugs were provided (Figure 3).
First, standard disease education was conducted using a
textbook that was created by our multidisciplinary team
based on the Textbook of Psychoeducation for Patients to
Understand Schizophrenia [17]. Changes in psychiatric
symptoms expected to occur by initiation of the MDP
were examined individually, and warning signs of symp-
tom aggravation were confirmed with the MDP partici-
pants. Participants were assessed as having a good
understanding of this point as they appeared convinced
by the examination outcome. Details of “warning signs”
are shown in Table 2. We created a monitoring sheet of
“warning signs” and referred to it as the “crisis plan”. A
“crisis plan” was created for almost all subjects in the
MTSA ward in Japan. In the “crisis plan”, the symptoms
(“warning signs”) that appear in a step-by-step fashion
with aggravation of the disease were indicated, and the
coping skills and surrounding support methods for
“warning signs” were provided. Creating a “crisis plan” isexpected to facilitate the subjects’ understanding of the
characteristics of and treatments for the disease and to
raise the ability to self-manage the disease. Details of the
“crisis plan” have been reported previously [18]. The
medication readministration criteria were determined by
the multidisciplinary team based on their clinical experi-
ence, as no preceding study existed. Members of the
team conferred in detail regarding readministration cri-
teria, as if the criteria are too loose, symptoms may be
aggravated so much that subjects harm others or them-
selves, and if criteria are too strict, subjects will not have
the opportunity to increase their awareness of the effects
of psychiatric drugs. When the medication readministra-
tion criteria were decided, patients’ opinions were also
taken into account. While subjects originally stated that
they did not require medication, one subject believed
their symptoms were manageable without medication, if
they had four or less symptoms categorized at level 1
according to the medication readministration criteria.
Coincidentally, the draft of the criteria, based on the
clinical experience of the multidisciplinary team, coin-
cided with subject comments. Subsequently, this evalu-
ation was also used for making a decision. After
consideration of these points, medication readministra-
tion criteria were selected. The basic attitude of the
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MDP forcibly in a way that would invoke conflict
between physicians and MDP subjects who did not
recognize the need for medication and treatment but in-
stead to examine the need for medication and the risks
of recurrence in a safe way together with the subjects
through the program.
Medication discontinuation period After the discon-
tinuation of medication, the presence/absence and de-
grees of “warning signs” and changes in psychiatric
symptoms were confirmed every day using monitoring
sheets between the multidisciplinary team and MDP par-
ticipants, so they could share the fact that the subjects
had reached an acceptable level for medication read min-
istration criteria. After initiation of the program, subjectsTable 3 Subscales of the Drug Attitude Inventory-30 (DAI-30)
Subscales of the DAI-30 Questions
Awareness of the need for medication 1. I don’t need to take med
4. Even when I am not in h
5. If I take medication, it’s o
8. I take medications of my
13. I take medication only
17. I know better than the
22. I should keep taking m
24. It is up to the doctor to
27. I am given medication
30. By staying on medicatio
Awareness of the effects of psychiatric drugs 2. For me, the good things
6. I am more aware of wha
9. Medications make me fe
10. I am no different on or
15. I get along better with
18. I feel more normal on m
21. My thoughts are cleare
23. Taking medication will
26. I am happier and feel b
29. I am in better control o
Impression of medication 3. I feel strange, “doped up
7. Taking medication will d
11. The unpleasant effects
12. Medication makes me f
14. Medication is slow-actin
16. I can’t concentrate on a
19. I would rather be ill tha
20. It is unnatural for my m
25. Things that I could do
28. I can’t relax on medicatwere allowed to take sleep-inducing drugs, but not anti-
psychotic drugs. However, if subjects wished to take anti-
psychotic drugs, they were permitted to take them, and
the MDP proceeded to the Medication readministration
period at that point. In conducting the MDP, antipsychotic
medication was decreased at a rate of chlorpromazine-
equivalent 50 mg per week and discontinued to reduce
the risk of withdrawal syndrome.Medication readministration period Even after anti-
psychotic drugs were restarted by reaching the medication
readministration criteria, subjective and objective changes
in psychiatric symptoms were confirmed using the moni-
toring sheet, and the need for medication and risks of re-
currence were examined between the multidisciplinaryication once I feel better.
ospital, I need medication regularly.
nly because of pressure from other people.
own free will.
when I feel ill.
doctors when to stop taking medication.
edication even if I feel well.
decide when I should stop taking medication.
to control behavior that other people (not myself) don’t like.
n, I can prevent myself getting sick.
about medication outweigh the bad.
t I am doing, of what is going on around me, when I am on medication.
el more relaxed.
off medication.
people when I am on medication.
edication.
r on medication.
prevent me from having a breakdown.
etter when I am taking medication.
f myself when taking medication.
”, on medication.
o me no harm.
of medication are always present.
eel tired and sluggish.
g poison.
nything when I am taking medication.
n take medication.
ind and body to be controlled by medication.
easily are much more difficult when I am on medication.
ion.
Table 4 Factors measured in the early stages of the
recovery phase
Intervention
group (n = 7)
Non-intervention





Age 45.3 ± 9.3 43.1 ± 11.4
Full-scale IQ 91.7 ± 14.7 92.8 ± 15.1
Years of education 15.4 ± 2.5 14.4 ± 2.6
DUP (year) 7.5 ± 7.5 3.2 ± 4.6
Treatment duration (year) 3.0 ± 4.5 9.8 ± 12.6
GAF 52.4 ± 7.1 53.1 ± 10.2
Family members living together Present: 4 Present: 14
Absent: 3 Absent: 3
Main antipsychotic drug OLZ: 5 OLZ: 10
RIS: 3
RIS: 2 QTP: 3
ARP: 1
CP equivalents (mg) 414.3 ± 211.6 698.9 ± 498.2
Self-discontinuation of antipsychotic
medication
Present: 4 Present: 14
Absent: 3 Absent: 3
DUP duration of untreated psychosis, GAF Global Assessment of Functioning,
CP chlorpromazine, OLZ olanzapine, RIS risperidone, QTP quetiapine,
ARP aripiprazole.
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pharmaceutical benefits.
Evaluation methods
Patients’ characteristics Factors that are considered to
affect medication adherence in the early stages of the re-
covery phase before conducting the MDP were com-
pared between the intervention and non-intervention
groups.
Medication adherence The DAI-30 was conducted, and
the utility of the MDP was examined based on differ-
ences between DAI-30 scores before and after the imple-
mentation of the MDP in the intervention group (n = 7).
To examine the long-term effects of the MDP, the DAI-
30 was conducted in the intervention group after they
had been shifted to the rehabilitation phase (6–14
months after the restart of medication). To examine
changes in factors affecting medication adherence, items
of the DAI-30 were categorized into three subscales:
“awareness of the need for medication”, “awareness of
the effects of psychiatric drugs”, and “impression of
medication” (Table 3).
Effect of excluding other programs To confirm whether
other programs were affecting the DAI-30 scores, we
compared the DAI-30 scores in the same period in the
non-intervention group (n = 17). For the non-intervention
group, the initial evaluation was conducted in the early
stages of the recovery phase and a second evaluation was
conducted 30.3 ± 7.7 days later.
Changes in psychiatric symptoms after the imple-
mentation of the MDP The Brief Psychiatric Rating
Scale (BPRS) was used for continuous evaluation of the
levels of aggravation resulting from medication discon-
tinuation in the intervention group.
Statistics The two-sample t-test was conducted to com-
pare DAI-30 scores before and after the implementation
of the MDP in the intervention group and in the same
period of non-intervention group at the 0.05 significance
level. Mann-Whitney U test and Fisher’s exact test were
conducted to compare patients’ characteristics between
the intervention and non-intervention groups at the 0.05
significance level. SPSS PASW Statistics 18 (SPSS Co.,
Ltd., Tokyo, Japan) was used for statistical analysis.
Results
Patients’ characteristics in the intervention and non-
intervention groups are shown in Table 4. Although the
significance of the statistical processing is poor, as the
sample size is so small, we compared characteristics that
were considered to affect medication adherence betweenthe two groups. No significant differences were observed
by the Mann-Whitney U test and Fisher’s exact test
(data not shown).
Table 5 shows changes in the DAI-30 score in the
intervention group. The total DAI-30 score significantly
increased after the completion of the MDP in the inter-
vention group (P = 0.002) (Figure 4A). In this group, the
mean total score of the DAI-30 was 18.3 ± 9.2 after com-
pletion of the MDP and 19.9 ± 8.5 after shifting to the
rehabilitation phase. Although no significant elevation
was observed in DAI-30 score after shifting to the re-
habilitation phase, the score was similar to or slightly
higher than that measured after completion of the MDP.
No significant differences were observed in the total
DAI-30 score between the initial evaluation and after
evaluation in the non-intervention group (Table 6).
Significant elevations after completion of the MDP
were also observed in the scores for all subscales of the
DAI-30, that is, “awareness of the need for medication,”
“awareness of the effects of psychiatric drugs,” and “im-
pression of medication” (P = 0.015, P = 0.002, and P =
0.014, respectively); however, there were no elevations in
the non-intervention group (Figure 4B–D, respectively).
The period of time before readministering anti-
psychotic drugs was 2 days at the earliest and 36 days at
the latest. After the readministration of antipsychotic
drugs, BPRS scores rapidly decreased to the same level
Figure 4 Changes in the Drug Attitude Inventory-30 (DAI-30) score from the Medication Discontinuation Program (MDP) intervention
group (n = 7) and non-intervention group (n = 17). The DAI-30 was conducted before and after implementation of the MDP in the intervention
group. In the non-intervention group, initial evaluation was conducted in the early stages of the recovery phase and a second evaluation was
conducted 30.3 ± 7.7 days later. The DAI-30 scores are shown by box-and-whisker plots. Black triangles indicate the median value in each
group. In the intervention group, the mean scores of the DAI-30 measured before and after the MDP are as follows: (A) Total: −2.6 ± 13.2 and
18.3 ± 9.2 (P = 0.002); (B) “awareness of the need for medication”: 0.9 ± 4.9 and 5.7 ± 4.2 (P = 0.015); (C) “awareness of the effects of psychiatric
drugs”: −4.6 ± 4.7 and 5.1 ± 3.8 (P = 0.002); (D) “impression of medication”: 1.1 ± 5.1 and 7.4 ± 2.2 (P = 0.014). Before: before the MDP, After: after
the MDP, Initial: initial evaluation, Second: second evaluation. *P < 0.01, **P < 0.05 by the two-sample t-test.
Table 5 Changes in Drug Attitude Inventory-30 (DAI-30) score in the intervention group
Before After After shifting to the recovery phase Period of time
before readministering
antipsychotic drugs
Case 1 −14 4 6 (10 months after completion of the MDP) 2 days
Case 3 −8 10 16 (6 months after) 15 days
Case 4 −8 26 26 (8 months after) 9 days
Case 5 14 20 20 (14 months after) 14 days
Case 6 8 28 30 (6 months after) 15 days
Case 7 10 26 27 (7 months after) 36 days
Case 8 −20 14 14 (6 months after) 27 days
Mean ± SD −2.6 ± 13.2 18.3 ± 9.2 19.9 ± 8.5
Before means before the Medication Discontinuation Program (MDP); After means after the MDP.
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Table 6 Changes in Drug Attitude Inventory-30 (DAI-30)
scores in the non-intervention group
Initial Second
Case a 0 0
Case b 14 6
Case c 4 2
Case d 24 24
Case e 10 0
Case f 4 12
Case g 18 12
Case h 10 28
Case i 4 8
Case j 2 10
Case k 26 30
Case l 26 20
Case m 22 −14
Case n 14 28
Case o 10 12
Case p 26 28
Case q 20 22
Mean ± SD 13.8 ± 9.1 13.4 ± 12.5
Initial means initial evaluation; Second means second evaluation.
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in all subjects in the intervention group (Table 7).
Discussion
Utility of the MDP
In the intervention group, the total score on the DAI-
30 and scores for the subscales significantly improved
after the MDP. These results suggest that the MDP
may help improve medication adherence. Furthermore,
score reductions were not observed even approximately
6–14 months after the program, indicating the possibil-
ity of long-term effects of the MDP. However, no sig-
nificant elevations of DAI-30 scores were observed in
the non-intervention group during the study, suggest-
ing that other treatment programs conducted during
MDP implementation or after completion of the MDP
do not affect DAI-30 score. This result also might
indicate that the DAI-30 scores were relatively stable
over time in patients who were in non-acute phases of
schizophrenia.
In the intervention group, the total score for DAI-30
and those for the subscales significantly improved, pos-
sibly because the MDP had multidirectional and stimula-
tory effects on each factor relating to the improvement
of medication adherence. Success in the establishment
of a treatment alliance, which was facilitated by conduct-
ing a team-based program including the subject basedon individual needs, may also have contributed to the
improvement in DAI-30 scores.
Morken et al. reported that one-sided education and
interventions by medical providers are not effective in
improving medication adherence, so a patient’s proactive
involvement in interventions is needed [19]. Further-
more, Dolder et al. reported that the improvement in ad-
herence was seen in interventions using a combination
of educational, behavioral, and affective strategies. They
also described that longer interventions and an alliance
with therapists appeared important for successful out-
comes [20].
The MDP is also an intervention using a combination
of educational, behavioral, and affective strategies in
which patients can be proactively involved. Furthermore,
this program is a long-term intervention that lasts for a
maximum of 6 months because the program involves
disease education and monitoring of “warning signs”
before, during, and after the discontinuation of medica-
tion. Strong and trusting relationships that serve as a
basis of treatment alliance may have been structured
during this long-term intervention. These factors may
explain how the MDP contributed to improving medi-
cation adherence.
A withdrawal case
Case 2, who withdrew from the MDP, had a high IQ but
had marked cognitive dysfunction. He did not reject
pharmacotherapy and psychosocial treatment provided
by the multidisciplinary team but had a passive attitude
toward it, so he could not deepen his insight into the
disease. However, he wished to participate only in the
MDP and showed an active attitude toward it.
Amador et al. reported that hallucinations, loss of
pleasure, and reduced sociality are more easily recog-
nized than delusions and thought disturbances by pa-
tients with schizophrenia, and indicated that whether or
not patients can acquire insight is associated with symp-
toms of schizophrenia [21].
Case 2 did not present hallucinations, loss of pleasure,
and reduced sociality but had delusions and thought dis-
turbances, which are considered difficult for patients to
become aware of. Furthermore, case 2 showed marked
alterations in his personality, such as cynical, arrogant,
and unnatural behaviors. Therefore, he was unable to
notice changes in his condition after discontinuation of
antipsychotic drugs, and it was difficult to evaluate him
objectively. These results might suggest that, for patients
with barely noticeable hallucinations and main clinical
features of delusions and thought disturbances, and
those with chronic schizophrenia who present marked
alterations in personality, the MDP is not suitable. Fur-
ther study should be performed to examine this point in
a larger number of subjects.





BPRS subscale items Total BPRS score
at readministration
of medication





1 38 Positive 29 41 Positive 30 38 Positive 29
Negative 3 Negative 3 Negative 3
Neurotic 6 Neurotic 8 Neurotic 6
3 26 Positive 14 41 Positive 23 26 Positive 14
Negative 6 Negative 6Negative 6
Neurotic 6 Neurotic 12 Neurotic 6
4 31 Positive 16 40 Positive 22 31 Positive 16
Negative 6 Negative 6 Negative 6
Neurotic 9 Neurotic 12 Neurotic 9
5 24 Positive 11 29 Positive 19 23 Positive 11
Negative 5 Negative 4 Negative 5
Neurotic 8 Neurotic 6 Neurotic 7
6 20 Positive 11 31 Positive 18 20 Positive 11
Negative 5 Negative 5
Neurotic 4 Negative 6
Neurotic 7 Neurotic 4
7 29 Positive 17 35 Positive 21 26 Positive 14
Negative 4 Negative 4 Negative 4
Neurotic 8 Neurotic 10 Neurotic 8
8 25 Positive 13 28 Positive 16 24 Positive 13
Negative 5 Negative 3 Negative 4
Neurotic 7 Neurotic 9 Neurotic 7
2 40 Positive 24 42 Positive 25 43 Positive 25
Negative 9 3 months after MDP
implementation
Negative 9 1 year after MDP
implementation
Negative 10
Neurotic 7 Neurotic 8 Neurotic 8
Positive means positive symptoms; Negative means negative symptoms; Neurotic means neurotic symptoms.
Murasugi et al. Annals of General Psychiatry  (2015) 14:11 Page 11 of 13Limitations
This study has several limitations. First, the sample size
was small. The MDP should be performed for patients
who meet the strict criteria: those who strongly deny
their disease, refuse to take medication, and wish to dis-
continue medication, patients who can verbally describe
changes in their medical conditions, have a certain level
of IQ and are not likely to hide their medical condition.
However, the availability of such patients was extremely
limited. Furthermore, we cannot perform a clinical study
that may interfere with healing, as we treat patients in
the forensic ward based on the national policy, and are
obliged to rehabilitate patients promptly. Performing the
program for patients treated under the MTSA requires
much effort and remains a major issue that needs to be
examined in the future.
Second, as an evaluation scale, we used DAI-30, which
is a self-completed questionnaire. The change in patients’attitudes to medication is a crucial point in this study.
Therefore, an objective evaluation scale should be used.
Unfortunately, such an evaluation scale does not exist at
present. After the completion of the MDP, the multidiscip-
linary team actually observed an improvement in medica-
tion adherence, acceptance of the disease, and reduction
in the resistance to medical treatment in the subjects.
Furthermore, to evaluate the effects of the program, rating
scales and the assessment of health status during
hospitalization are insufficient. Long-term follow-up
based on medication adherence, changes in health sta-
tus, and living status after hospital discharge is needed.
We are currently performing a follow-up investigation
involving subjects who completed hospitalized treatment
in our department and shifted to outpatient treatment.
Third, in our study, we used medication readministra-
tion criteria that were not validated objectively. Subjects
were carefully selected and medical conditions of subjects
Murasugi et al. Annals of General Psychiatry  (2015) 14:11 Page 12 of 13undergoing medication discontinuation were regularly
and carefully assessed by the multidisciplinary team.
Therefore, while we may be able to execute a program
safely using these medication readministration criteria,
this does not necessarily ensure the complete reliability
of the program. We cannot exclude the possibility of
discrepancies as the safety of the MDP has not been af-
firmed. Further study is essential in determining the
best medication readministration criteria.
Although this study has some limitations, we think the
MDP might become a useful treatment program to im-
prove medication adherence, an important issue in the
treatment of schizophrenia. The BPRS scores worsened
after medication discontinuation, although they recov-
ered promptly after medication readministration. These
results suggest that this program was executed safely. A
randomized case-control study will be needed to prove
the validity of the MDP in the future. However, as men-
tioned above, there are several difficulties in using such
a research design at our ward. The selection of the con-
trol group is particularly difficult. Some consideration is
needed to address this point. For example, one solution
may be to measure DAI-30 for a certain fixed period in
subjects in the intervention group before MDP interven-
tion and use these DAI-30 scores as control data. After
that, subjects would undergo the same intervention re-
ported in this paper. This design might be considered a
quasi-case control study. We expect that the MDP will
be tried not only in the judicial ward but many general
psychiatric care institutions to clarify both its usefulness
and limitations. In the process, MDP will become fur-
ther refined. At that time, MDP may be applicable not
only to medical care for mentally ill offenders but also to
the treatment of schizophrenia.Conclusions
We conducted the MDP that was developed to increase
awareness of the effects of psychiatric drugs and im-
prove medication adherence. Our study suggests that
the MDP has the possibility of improving medication ad-
herence and might have multidirectional and stimulatory
effects on each factor relating to this improvement. It
was also suggested that the effects of the MDP may be
maintained over a long duration. However, this is a pilot
study and has some limitations. Further studies should
be performed to replicate the present finding in a larger
number of subjects.Abbreviations
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